Trials / Active Not Recruiting
Active Not RecruitingNCT06594146
Study of CM313 (SC) Injection in Subjects With Primary Immune Thrombocytopenia (ITP)
A Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Initial Efficacy of CM313 (SC) Injection in Subjects With Primary Immune Thrombocytopenia
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 62 (actual)
- Sponsor
- Keymed Biosciences Co.Ltd · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This is a randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and initial efficacy of CM313 (SC) injection in patients with primary immune thrombocytopenia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CM313 injection | CM313 |
| OTHER | placebo | placebo |
Timeline
- Start date
- 2024-11-11
- Primary completion
- 2025-12-30
- Completion
- 2025-12-30
- First posted
- 2024-09-19
- Last updated
- 2025-04-23
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06594146. Inclusion in this directory is not an endorsement.